TransCode Therapeutics, CFO Tom Fitzgerald Plans To Retire; John Tattory To Serve As Interim Finance Chief, Effective Immediately

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald. John Tattory, will serve as Interim Chief Financial Officer, effective immediately.